Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > FDA Hold

<< Previous

Bullboard Posts

Next >>

Comment by Duster340on Apr 01, 2024 11:06am

257 Views

Post# 35962827

RE:FDA Hold

mstrmnds wrote: It's because of harm to patients due to insufficient funding (safety monitoring)

It has nothing to do with Otena

That is right they have no money to run P2, that means they could not find anyone to finance them, all avenues must be exhausted by now. and nuance wants there money. it is over, some investors are blind and do not seem to be able to put 2+2 together. hard to beleive the stock is above 20 cents, my guess it will be a dime or lower soon.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec